PUBLISHER: The Business Research Company | PRODUCT CODE: 1829778
PUBLISHER: The Business Research Company | PRODUCT CODE: 1829778
Point-of-care (POC) coagulation testing devices are portable, easy-to-use medical devices used to assess the clotting ability of blood outside of a traditional laboratory setting. They are designed to provide rapid and accurate results, allowing healthcare providers to make immediate treatment decisions for patients with coagulation disorders or those at risk of abnormal bleeding or clotting.
The main products of point-of-care (POC) coagulation testing devices are coagulation monitors, consumables, and coagulation analyzers. Coagulation monitors are medical devices used to measure the clotting ability of blood, typically in a point-of-care (POC) setting. They work by using various technologies, including optical technology, mechanical technology, and electrochemical technology, and follow prothrombin time and international normalized ratio, viscoelastic coagulation monitoring, and other methods. The different applications include blood glucose testing, infectious diseases testing, cardiac markers testing, coagulation testing, blood gas and electrolyte testing, and others, and are used by hospitals, diagnostic laboratories, clinics, and others.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp increase in U.S. tariffs and resulting trade tensions in spring 2025 are significantly impacting the medical equipment sector, especially for imported components used in imaging machines, surgical-grade stainless steel, and disposable plastics. With hospitals and clinics pushing back against price increases, manufacturers are facing margin pressure. The situation is further complicated by regulatory challenges, as switching suppliers due to tariffs often necessitates re-certification of medical devices, leading to delays in market entry. In response, companies are mitigating risks by dual-sourcing key components, ramping up domestic production of standardized items, and accelerating research into more cost-effective materials.
The point-of-care (POC) coagulation testing devices market research report is one of a series of new reports from The Business Research Company that provides point-of-care (POC) coagulation testing devices market statistics, including point-of-care (POC) coagulation testing devices industry global market size, regional shares, competitors with a point-of-care (POC) coagulation testing devices market share, detailed point-of-care (POC) coagulation testing devices market segments, market trends and opportunities, and any further data you may need to thrive in the point-of-care (POC) coagulation testing devices industry. This point-of-care (POC) coagulation testing devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The point-of-care (poc) coagulation testing devices market size has grown strongly in recent years. It will grow from $2.12 billion in 2024 to $2.32 billion in 2025 at a compound annual growth rate (CAGR) of 9.8%. The growth in the historic period can be attributed to growing prevalence of infectious and chronic diseases, increasing geriatric population, increasing use of miniaturized portable instruments, growing use of biomarker profiling, and growing demand for personalized medicine.
The point-of-care (poc) coagulation testing devices market size is expected to see strong growth in the next few years. It will grow to $3.27 billion in 2029 at a compound annual growth rate (CAGR) of 9.0%. The growth in the forecast period can be attributed to rise in demand for rapid and accurate diagnosis of disease, growing emphasis on wellness and preventive healthcare, the growing demand for rapid and on-site diagnostic testing, rise in infectious disease outbreaks, and rise of telemedicine. Major trends in the forecast period include next-generation sequencing (NGS) integration, RNA detection and analysis, single-cell PCR analysis, bioinformatics software and data analysis tools, microfluidic technologies, lab-on-a-chip systems, and point-of-care testing (POCT), artificial intelligence (AI) and data analytics.
The forecast of 9.0% growth over the next five years reflects a modest reduction of 0.7% from the previous estimate for this market.This reduction is primarily due to the impact of tariffs between the US and other countries. This is likely to directly affect the US through supply chain disruptions for capillary blood collection components and disposable test cartridges, key imports from Ireland and Singapore, potentially delaying emergency coagulation testing.The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The increasing prevalence of blood clotting disorders is expected to drive the growth of the point-of-care (POC) coagulation testing devices market. Blood clotting disorders affect the blood's ability to form clots properly. Lifestyle factors, such as smoking, excessive alcohol consumption, and a sedentary lifestyle, can contribute to these disorders by impacting blood vessel health, clotting factor levels, and blood flow, which in turn increases the risk of abnormal clot formation. POC coagulation testing devices allow healthcare providers to quickly assess a patient's coagulation status, enabling timely adjustments to medication dosages and treatment plans. For instance, in October 2023, the World Federation of Hemophilia, a Canada-based non-profit organization, reported that in 2022, 427,685 individuals were affected by bleeding disorders, with 257,146 people diagnosed with hemophilia-208,957 with Hemophilia A, 42,203 with Hemophilia B, and 5,986 with an unspecified type of hemophilia. Additionally, 70,034 people were affected by other bleeding disorders. As a result, the growing prevalence of blood clotting disorders is driving the expansion of the POC coagulation testing devices market.
Leading companies in the POC coagulation testing devices market are developing immunofluorescence-based quantitative analyzers to enhance the diagnosis and management of coagulation disorders. These analyzers are used in laboratories to measure and quantify specific proteins or molecules involved in the coagulation process, aiding in the diagnosis and management of blood clotting disorders. For instance, in January 2023, Cipla Limited, an India-based pharmaceutical company, launched Cippoint, an immunofluorescence-based quantitative analyzer. Cippoint utilizes immunofluorescence technology to deliver rapid and accurate test results within 3 to 15 minutes, facilitating faster clinical decision-making. Its user-friendly interface, quick turnaround time, and comprehensive testing capabilities make Cippoint crucial for improving diagnostic efficiency and patient care outcomes.
In August 2024, Perosphere Technologies Inc., a US-based medical device manufacturing company, partnered with M3 Medical for an undisclosed amount. The partnership aims to enhance patient outcomes, reduce healthcare system costs, and establish a new standard of care for patients using anticoagulant therapies or those at risk of bleeding in Ireland. M3 Medical is an Ireland-based medical device company.
Major companies operating in the point-of-care (POC) coagulation testing devices market are Roche Diagnostics, Thermo Fisher Scientific Inc., Abbott Laboratories, Medtronic plc, Siemens Healthineers, Koninklijke Philips N.V., Bio-Rad Laboratories Inc., Werfen, Haemonetics Corporation, Sonora Quest Laboratories, 23andMe Holding Co, Thorne HealthTech Inc., Metropolis Healthcare Limited, Color Health Inc, LetsGetChecked Inc., Ambry Genetics Corporation, MyHeritage Ltd, Genova Diagnostics Inc., Everlywell Inc., Complete Genomics Incorporated, DanteLabs Inc., HemoSonics LLC, Gene by Gene Ltd., Veritas Intercontinental, DirectLabs LLC, Full Genomes Corporation Inc., Ulta Lab Tests LLC, WellnessFX Inc., Any Lab Test Now Inc.
North America was the largest region in the point-of-care (POC) coagulation testing devices market in 2024. The regions covered in the point-of-care (POC) coagulation testing devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the point-of-care (POC) coagulation testing devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The point-of-care (POC) coagulation testing devices market consists of revenues earned by entities by providing services such as increased patient comfort, improved workflow efficiency, better patient management, remote monitoring capabilities, emergency use for immediate testing, and assessment of anticoagulant reversal effectiveness. The market value includes the value of related goods sold by the service provider or included within the service offering. The point-of-care (POC) coagulation testing devices market also includes sales of viscoelastic testing devices, platelet function testing devices, and D-Dimer testing devices. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Point-of-Care (POC) Coagulation Testing Devices Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on point-of-care (poc) coagulation testing devices market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for point-of-care (poc) coagulation testing devices ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The point-of-care (poc) coagulation testing devices market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.